The first biosimilar for the treatment of breast and stomach cancers has been approved by the FDA, termed Ogivri.
Browsing: Drug Discovery and Development
MorphoSys (Munich, Germany) has announced that its licensee Janssen (Beerse, Belgium) has gained approval for Tremfya® in Europe. The monoclonal antibody is used for the treatment of plaque psoriasis.
For therapeutic drug development and monitoring, microsampling technology provides a breakthrough alternative
One useful way to think about volumetric absorptive microsampling (VAMS) technology is as the next generation of traditional dried blood spot (DBS) cards. It’s a simpler method that makes it easier to collect blood and prepare it for analysis. With minimal training, the microsampling process can be self-administered anywhere, through a procedure that is less difficult and generally less expensive than working with conventional venous blood. Other benefits include a more pleasant patient experience, which leads to greater adherence and compliance, and freer access to remote areas of the world.
All biological protein drugs are immunogenic, which may lead to severe clinical consequences. This makes knowledge of the scientific and regulatory aspects of immunogenicity a must for every drug manufacturer.
Biotechnology company, BIOCAD (St. Petersburg, Russia), announced that its rituximab biosimilar has received recommendation for approval in India.
Novel ‘heart-on-a-chip’ technology could measure compound effects on heart tissue function in the hope of ensuring safety and efficiently of new drugs.
A blood test could predict how men diagnosed with advanced prostate cancer respond to targeted disease treatments.
Plasma protein binding monitoring of therapeutic drugs in patients using single set of hollow fiber centrifugal ultrafiltration
In this study, a novel method was proposed to analyze free drug concentration and total drug concentration.
NGM Biopharmaceuticals announce product–NGM282–achieves primary endpoint in non-alcoholic steatohepatitis Phase II Trial
Non-alcoholic steatohepatitis patients administered with NGM282 demonstrated dramatically reduced liver fat and improvements in other biomarkers of liver function.
Researchers demonstrated that a modified form of HEG1 protein could be a diagnostic tool for malignant mesothelioma.